Accuray Incorporated (0H8I.L)
USD 1.47
(2.4%)
USD 1.47
(2.4%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 504 Thousand USD | -90.08% |
| 2022 | 5.08 Million USD | -37.63% |
| 2021 | 8.14 Million USD | -63.36% |
| 2020 | 22.23 Million USD | 63.03% |
| 2019 | 13.63 Million USD | 554.78% |
| 2018 | 2.08 Million USD | 154.86% |
| 2017 | -3.79 Million USD | 61.35% |
| 2016 | -9.82 Million USD | -743.29% |
| 2015 | 1.52 Million USD | 107.97% |
| 2014 | -19.16 Million USD | -5.65% |
| 2013 | -18.14 Million USD | 74.64% |
| 2012 | -71.55 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 FY | 504 Thousand USD | -90.08% |
| 2023 Q2 | -3.96 Million USD | -279.12% |
| 2023 Q3 | -4.56 Million USD | -15.09% |
| 2023 Q4 | 6.81 Million USD | 249.43% |
| 2023 Q1 | 2.21 Million USD | 584.25% |
| 2022 Q4 | -457 Thousand USD | -114.67% |
| 2022 FY | 5.08 Million USD | -37.63% |
| 2022 Q3 | 3.11 Million USD | 15.19% |
| 2022 Q2 | 2.7 Million USD | 223.97% |
| 2022 Q1 | -2.18 Million USD | -206.54% |
| 2021 Q1 | 2.41 Million USD | -41.79% |
| 2021 Q2 | 3.98 Million USD | 65.12% |
| 2021 Q3 | -292 Thousand USD | -107.33% |
| 2021 Q4 | 2.04 Million USD | 801.37% |
| 2021 FY | 8.14 Million USD | -63.36% |
| 2020 Q3 | 4.42 Million USD | -46.02% |
| 2020 Q1 | 5.46 Million USD | 4.61% |
| 2020 Q4 | 4.14 Million USD | -6.42% |
| 2020 Q2 | 8.19 Million USD | 49.95% |
| 2020 FY | 22.23 Million USD | 63.03% |
| 2019 Q4 | 5.22 Million USD | -34.41% |
| 2019 Q1 | -4.28 Million USD | -231.37% |
| 2019 Q2 | 3.62 Million USD | 184.65% |
| 2019 FY | 13.63 Million USD | 554.78% |
| 2019 Q3 | 7.96 Million USD | 119.96% |
| 2018 Q4 | 3.25 Million USD | 13.09% |
| 2018 Q3 | 2.88 Million USD | 431.91% |
| 2018 Q2 | -868 Thousand USD | 81.48% |
| 2018 Q1 | -4.68 Million USD | -251.57% |
| 2018 FY | 2.08 Million USD | 154.86% |
| 2017 Q1 | -2.05 Million USD | -172.9% |
| 2017 FY | -3.79 Million USD | 61.35% |
| 2017 Q4 | 3.09 Million USD | 180.95% |
| 2017 Q3 | -3.82 Million USD | -275.71% |
| 2017 Q2 | -1.01 Million USD | 50.44% |
| 2016 Q4 | 2.81 Million USD | 322.0% |
| 2016 Q3 | -1.26 Million USD | 73.71% |
| 2016 Q2 | -4.82 Million USD | 26.33% |
| 2016 Q1 | -6.54 Million USD | -121.18% |
| 2016 FY | -9.82 Million USD | -743.29% |
| 2015 Q4 | -2.96 Million USD | -154.39% |
| 2015 Q1 | -7.23 Million USD | -570.78% |
| 2015 Q3 | 5.44 Million USD | 4488.71% |
| 2015 Q2 | -124 Thousand USD | 98.29% |
| 2015 FY | 1.52 Million USD | 107.97% |
| 2014 FY | -19.16 Million USD | -5.65% |
| 2014 Q4 | -1.07 Million USD | -191.98% |
| 2014 Q1 | -15.27 Million USD | -227.23% |
| 2014 Q3 | 1.17 Million USD | 132.64% |
| 2014 Q2 | -3.59 Million USD | 76.49% |
| 2013 Q1 | -12.28 Million USD | 1.91% |
| 2013 Q3 | -475 Thousand USD | 33.66% |
| 2013 Q4 | -4.66 Million USD | -882.53% |
| 2013 FY | -18.14 Million USD | 74.64% |
| 2013 Q2 | -716 Thousand USD | 94.17% |
| 2012 Q4 | -12.52 Million USD | 37.79% |
| 2012 Q3 | -20.13 Million USD | -9.63% |
| 2012 Q2 | -18.36 Million USD | 0.0% |
| 2012 FY | -71.55 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Phreesia, Inc. | -131.77 Million USD | 100.382% |
| Align Technology, Inc. | 643.33 Million USD | 99.922% |
| Elevance Health Inc. | 133.96 Billion USD | 100.0% |
| AxoGen, Inc. | -21.46 Million USD | 102.348% |
| Boston Scientific Corporation | 2.34 Billion USD | 99.978% |
| CVS Health Corporation | 13.74 Billion USD | 99.996% |
| Cardinal Health, Inc. | 1.24 Billion USD | 99.959% |
| Centene Corporation | 2.93 Billion USD | 99.983% |
| DaVita Inc. | 1.6 Billion USD | 99.969% |
| HCA Healthcare, Inc. | 9.62 Billion USD | 99.995% |
| Hologic, Inc. | 970.2 Million USD | 99.948% |
| Humana Inc. | 4.01 Billion USD | 99.987% |
| IDEXX Laboratories, Inc. | 1.09 Billion USD | 99.954% |
| Laboratory Corporation of America Holdings | 725.6 Million USD | 99.931% |
| Masimo Corporation | 136.5 Million USD | 99.631% |
| McKesson Corporation | 3.9 Billion USD | 99.987% |
| Patterson Companies, Inc. | 252.92 Million USD | 99.801% |
| Quest Diagnostics Incorporated | 1.26 Billion USD | 99.96% |
| ResMed Inc. | 1.31 Billion USD | 99.962% |
| Henry Schein, Inc. | 615 Million USD | 99.918% |
| Teladoc Health, Inc. | -248.55 Million USD | 100.203% |
| Universal Health Services, Inc. | 1.17 Billion USD | 99.957% |
| Veeva Systems Inc. | 429.33 Million USD | 99.883% |
| Baxter International Inc. | 390 Million USD | 99.871% |
| Becton, Dickinson and Company | 2.11 Billion USD | 99.976% |
| Intuitive Surgical, Inc. | 1.76 Billion USD | 99.971% |
| Danaher Corporation | 5.38 Billion USD | 99.991% |
| Stryker Corporation | 3.88 Billion USD | 99.987% |
| Medtronic plc | 5.14 Billion USD | 99.99% |